Bangalore-based oncology focused start-up OncoStem Diagnostics has collaborated with CORE Diagnostics to distribute mammaCORE CanAssist-Breast — Indias first indigenously developed test to help early stage breast cancer patients determine their risk of cancer relapse.
The test is designed for ER+/PR+/Her2- Breast Cancer patients in Stages 1 and 2, a company statement said.
With no tests hitherto to predict risk of cancer recurrence, 95 per cent of patients get treated with chemo or radiotherapy but only about 20 per cent early stage patients actually recur. Thus, majority of patients are perhaps over-treated and have to bear toxic effects of the treatment which reduces their quality of life and is a monetary drain,” said Zoya Brar, Founder and MD, CORE Diagnostics.
“This test will help reduce this burden of over-treatment by helping doctors plan treatments while taking into account the risk of relapse. We are extremely excited about the power of this product and are looking forward to help modify the future of breast cancer treatment across the globe, Brar added.
The CanAssist-Breast test uses clinical parameters in combination with five novel biomarkers tested by a well-standardised technique which measures protein expression accurately and then integrates them into a statistical algorithm to stratify patients as low or high risk for recurrence, according to Dr Manjiri Bakre, Founder & CEO, OncoStem Diagnostics.
“Thus, using the CanAssist-Breast test, clinicians can plan personalized and optimum therapy for patients. CanAssist-Breast will spare more than 60,000 Breast Cancer patients in India per year and over 660,000 patients worldwide from severe chemotherapy associated toxic effects and costs. Our partnership with CORE Diagnostics will help make this test available to more Indians across the country, Bakre said.